← The feed Many Minded · The brief
HEALTH · forward · impact 3/5 · 2026-11-16

Osteoporosis Treatment Trial Shows 94% Fracture Reduction in First-In-Human Study

First-in-human trial with engineered stem cells reduced fragility fractures by 94% in patients with advanced osteoporosis.

A University of Murcia, Spain-led clinical trial published in *Cell* enrolled 10 women over 50 with advanced osteoporosis. Each received a single infusion of their own engineered mesenchymal stem/stromal cells (MSCs) coated with sugar. Over two years, participants sustained 94% fewer fragility fractures than before the infusion—reducing their annual fracture rate from 8 to 0.5. Bone tissue area increased by 70% at four months, while bone pain dropped 34% and disability scores fell 30% by year two. All patients were already taking osteoporosis medications, though the source specifies most were on other osteoporosis drugs.

The treatment involves engineering patients' own MSCs (20-30 micrometers in size) to improve bone marrow delivery. Researchers note MSCs typically lodge in lungs during first circulation without engineering, but the sugar coating likely enhanced bone targeting. The trial lacked a control group and did not track MSCs post-infusion to confirm bone marrow retention—a limitation observed in mouse studies where MSCs reached bone marrow.

This approach could significantly reduce fracture-related disability and healthcare costs for millions globally. If confirmed to work beyond two years and in larger populations, it may offer a more effective osteoporosis treatment than current medications alone. Researchers are preparing a follow-up trial with 100 patients randomized to receive either engineered MSCs from their own bone marrow, engineered MSCs from a healthy donor, or no treatment.

What to watch: Long-term effects beyond two years, whether fracture reduction stems from MSC activity or natural recovery patterns given patients were selected at peak fracture risk, and whether MSCs actually reach bone marrow as observed in animal studies. The trial’s small size and lack of control group mean results may not generalize to broader populations.

Source: ScienceAlert